ION Breast Cancer Clinical Pathways - ION Solutions

Small Cell Lung: Extensive Disease – Second LineChemotherapy:Platinol (Cisplatin) VP-16 (Etoposide) EP=High; FN=10%-20%Cisplatin 75-80mg/m 2 D1Etoposide 80-100mg/m 2 D1-3ORCisplatin 25mg/m 2 D1-3Etoposide 100mg/m 2 D1-3q 21 Day Cycle>> J Clin Oncol 20 :4665-4672, 2002>> J Clin Oncol 12 :2022-2034, 1994>> J Clin Oncol 3:1471-1477, 1985Paraplatin (Carboplatin) VP-16 (Etoposide) EP=Moderate; FN=10%-20%Carboplatin AUC 5-6 D1Etoposide 100mg/m 2 D1-3q 21 Day Cycle>> J Clin Oncol 17:3540-3545, 1999Platinol (Cisplatin) Camptosar (Irinotecan) EP=High; FN=10%-20%Cisplatin 60mg/m 2 D1Irinotecan 60mg/m 2 D1, D8, D15q 28 Day CycleORCisplatin 30mg/m 2 D1, D8Irinotecan 65mg/m 2 D1, D8q 21 Day Cycle>> N Engl J Med 346:85-91, 2002>> J Clin Oncol 24:2038-2043, 2006Taxol (Paclitaxel) EP=Low, FN=10%-20%Paclitaxel 175mg/m 2 D1 (or weekly equivalent)q 21 Day Cycle>> Br J Cancer 77:347-351, 1998>> Anticancer Res 26:777-781, 2006Taxotere (Docetaxel) EP=Low; FN=10%-20%Docetaxel 100mg/m 2 D1 (or weekly equivalent)q 21 Day Cycle>> Eur J Cancer 30A:1058-1060, 1994Camptosar (Irinotecan) EP=Moderate; FN> J Clin Oncol 10:1225-1229, 1992Page 32 of 39© 2013 by ION Solutions. All rights reserved